Literature DB >> 18045059

Jak2 tyrosine kinase and cancer: how good cells get HiJAKed.

Michael D Godeny1, Peter P Sayeski.   

Abstract

Cloned in 1992, Jak2 tyrosine kinase has emerged as a critical molecule in mammalian development, physiology, and disease. Here, we will review the early history of Jak2 as it pertains to its role in classical cellular signaling. We also review how specific structural determinants within Jak2 dictate its overall function. Finally, we will review relatively recent literature as it pertains to the role of Jak2 in neoplastic growth as well as the identification of novel Jak2 inhibitors. It is our hope that by reviewing these specific areas, we will have a better understanding of the role of Jak2 in cancer, and in turn, we may have a better idea as to how to block aberrant Jak2 function.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18045059     DOI: 10.2174/187152007782330105

Source DB:  PubMed          Journal:  Anticancer Agents Med Chem        ISSN: 1871-5206            Impact factor:   2.505


  2 in total

1.  ERK1/2 inhibition enhances apoptosis induced by JAK2 silencing in human gastric cancer SGC7901 cells.

Authors:  Cuijuan Qian; Jun Yao; Jiji Wang; Lan Wang; Meng Xue; Tianhua Zhou; Weili Liu; Jianmin Si
Journal:  Mol Cell Biochem       Date:  2013-11-01       Impact factor: 3.396

2.  The Jak2 small molecule inhibitor, G6, reduces the tumorigenic potential of T98G glioblastoma cells in vitro and in vivo.

Authors:  Rebekah Baskin; Sung O Park; György M Keserű; Kirpal S Bisht; Heather L Wamsley; Peter P Sayeski
Journal:  PLoS One       Date:  2014-08-27       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.